Dimerix Limited entered into an agreement with the NHMRC Clinical Trials Centre (CTC) at the University of Sydney to expand the CLARITY 2.0 clinical study to sites in Australia testing the Dimerix-developed drug candidate DMX-200 in COVID-19 patients with respiratory complications. An initial six sites will begin recruitment for the feasibility/Phase 3 study across New South Wales, Victoria and Queensland once regulatory and ethics approval is received. There are an estimated 26,448 active COVID-19 cases in Australia, and approximately 1,500 patients currently hospitalised. These numbers are expected to increase as border restrictions change over the coming months. Vaccines are critically important to reduce the severity of symptoms and spread of the disease. However, even as vaccination rates increase, it is anticipated that a significant proportion of the population will remain susceptible to COVID-19 because they are not vaccinated or do not get an adequate protective response from the vaccines. Therefore, it is still likely that a large number of people will get infected, with many ending up with COVID respiratory complications and potentially long-COVID, which refers to symptoms that extend long beyond recovery from the virus. As such, there remains a great need for treatments for patients with COVID-19 within Australia. The CLARITY 2.0 study, which is already approved and open for recruitment in India, will recruit an aggregate of 600 patients across both India and Australia. The NHMRC CTC will be the local sponsor in Australia, led by Professor Meg Jardine. Additional countries that could recruit patients for the study is also being investigated. The company's approach is based on a clear scientific rationale, unique and potentially complementary to others being investigated globally, and importantly if effective in this study, would likely be effective against any strain as well as potentially other pneumonias with a common mechanism of action.